Key Highlights

  • DataMEDS AI (NASDAQ:MEDS) was down 5.29% in premarket trading on October 9, 2026 on a listed price of USD 3.40, after closing up 18.06% on October 8, so the move is partly a giveback.
  • No DataMEDS announcement was found for October 8 or 9; the latest verified items are an October 5 notice on a meme coin distribution Record Date and an October 1 pharmacy Revenue update.
  • A September 18 settlement eliminated about USD 19 million of liabilities for USD 450,000 in cash and the retirement of about 364,099 shares, when the stock traded near USD 5.11.
  • The listed price of USD 3.40 is about 33% below that September 18 level, simple arithmetic, and trailing revenue of USD 8.02 million is down 78.2%, so the Business is shrinking.

What Moved DataMEDS Shares

DataMEDS AI (NASDAQ:MEDS) was indicated down 5.29% in the October 9, 2026 premarket session on the screener, on a listed price of USD 3.40 and premarket Volume of 17,377 shares. The listed price is the October 8 close, when the shares rose USD 0.52, or 18.06%. The screener lists no catalyst and a search found no company release or filing dated October 8 or 9, so the decline looks like a partial Reversal of that jump. Recent verified items include an October 5 reminder about a meme coin distribution record date and an October 1 report that its Corexa Pharmacy generated monthly revenue above USD 1 million, up more than 66% from July.

Settlement, Acquisition and Shrinking Revenue

On September 18, 2026 DataMEDS settled litigation over Debt tied to a 2023 membership purchase agreement with Wellgistics for USD 450,000 in cash and the retirement of about 364,099 shares, which the company said eliminated about USD 19 million of liabilities. It announced the acquisition of the Helomics AI cancer diagnostics lab from Axe Compute around September 15 to 16, launched a mobile app with Tollo Health on September 28 and completed a 1-for-50 reverse split on May 26. A published profile shows trailing revenue of USD 8.02 million, down 78.2%, against fiscal 2025 revenue of USD 23.34 million and a fiscal 2025 loss of USD 101.27 million.

Risks and What to Watch

The company has combined health information technology, pharmacy services and AI tools with a pivot toward digital assets, and the mix of strategies raises execution risk. DataMEDS AI (NASDAQ:MEDS) has shrinking revenue, large losses, a Market Value near USD 10 million and a 52-week range of USD 0.823 to USD 73.00, which reflects the reverse split and extreme volatility. Large daily swings, such as the 18.06% rise on October 8, can come with trading halts and offer little information about fundamentals. Investors should watch filings on financing, the meme coin plan, Corexa revenue and any listing notices. A premarket decline on 17,377 shares can change by the open.

Where Things Stand

DataMEDS AI (NASDAQ:MEDS) is down in premarket after an 18.06% jump on October 8, and no company announcement explains either move. The verified backdrop is a September settlement that removed about USD 19 million of liabilities, an acquisition, a May reverse split and sharply lower revenue. The balance of evidence is that this is a volatile giveback in a stock whose fundamentals remain weak and unclear. The next checkpoints are filings on financing and digital assets, Corexa revenue and any Nasdaq notices.